Evaluation of Serum s EGFR in Ovarian Tumors, its Comparison with Serum CA125, HE4 and Correlation with Histopathological Types
Tóm tắt
EGFR is deregulated, in several types of cancer, by three mechanisms: (1) activating gene mutations; (2) overexpression of the EGFR transmembrane form and (3) altered ligand expression. Selective EGFR inhibitors have been suggested as first-line therapy in lung cancer patients harboring EGFR mutations, tumors of the pancreas and certain histotypes of ovarian tumors. Carbohydrate antigen 125(CA125) and Human Epididymis 4 are being used routinely for detection and follow up of ovarian cancer globally.
A comparative observational study, over a 40 samples was carried out using Pre-operative and Post-operative Measurement of CA125 and HE4 by chemiluminescence and sEGFR by ELISA (Bioassay Technology Laboratory, Cat. No.E0313Hu). Results were compared between the three markers in various histological types of ovarian tumor using Statistical analysis (SPSS version 21.0).
A combined panel of serum sEGFR, CA125, and HE4 increases the specificity and efficiency in ovarian cancer diagnosis.
Tài liệu tham khảo
Ahmadi H, Djaladat H, Cai J, Miranda G, Daneshmand S. Precystectomy serum levels of carbohydrate antigen 19–9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder. Urol Oncol. 2014;32(5):648–56.
Montagnana M, Danese E, Giudici S, et al. HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem. 2011;55:1–20.
Khati S, Jaiswal R, Singh N. Evaluation of serum HE4 in ovarian tumors, its comparison with serum CA125 and correlation with histological subtypes. Indian J Gynecol Oncolog. 2018;16:62. https://doi.org/10.1007/s40944-018-0232-7.
Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to solid tumors. Cancer Discov. 2016;6(2):133–46.
Smith JB, Stashwick C, Powell DJ Jr. B7 H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol. 2014;34(1):181–9.
Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, et al. B7 H4 is over expressed in early stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol. 2007;106:334–41.
Jantus-Lewintre E, Sirera R, Cabrera A, Blasco A, Caballero C, et al. Analysis of the prognostic value of soluble Epidermal Growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2011;12:320–7.
Granados ML, Hudson LG, Samudio-Ruiz SL. Contributions of the Epidermal Growth factor receptor to acquisition of platinum resistance in ovarian cancer cells. PLoS ONE. 2015;10(9):e0136893.
Greenhalgh J, Dwan K, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non small cell lung cancer. Cochrane Database Syst Rev. 2016;25(5):CD010383.
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.
Teplinsky E, Muggia F. EGFR and HER2: is there a role in ovarian cancer? Transl Cancer Res. 2015;4(1):1–2.
Baron AT, Cora EM, Lafky JM, et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 2003;12(2):103–13.
Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer. Curr Health Sci J. 2018;44(2):129–34.
Cristea AE, Stepan AF, Zavoi RE, et al. EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors. Curr Health Sci J. 2018;44(2):129–34.
Li YZ, Wang ZC, Luo L, et al. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis. Eur Rev Med Pharmacol Sci. 2020;24:604–10.
Vrabie CD, Petrescu A, Waller M, Dina I. Clinical factors and biomarkers in ovarian tumors development. Rom J Morphol Embryol. 2008;49(3):327–38.